Elazar Rabbani et al. Serial No.: 08/978,634 Filed: November 25, 1997

Page 4 [Amendment Under 37 C.F.R. §1.115 (In Response

to the February 16, 1999 Office Action - August 17, 1999]

251. (Amended) The composition of claim 245, wherein said monomeric unit is selected from the group consisting of a naturally occurring compound, a modified natural compound, a synthetic compound, [and] a recombinantly produced compound, [or] and a combination thereof.

252. (Amended) The composition of claim 245, wherein said analyte-specific moiety is derived or selected from the group consisting of a protein, a polysaccharide, a fatty acid, [or] a fatty acid ester, [and] a polynucleotide, [or] and a combination of the foregoing.

253. (Amend

253. (Amended) The composition of claim 252, wherein said protein is selected from the group consisting of an antibody, a hormone, a growth factor, a lymphokine, [or] a cytokine, [and] a cellular matrix protein, [or] and a combination of any of the foregoing.

259. (Amended) The composition of claim 245, wherein said binding matrix is selected from the group consisting of a naturally occurring compound, a modified natural compound, a synthetic compound, [and] a recombinantly produced compound, [or] and a combination thereof.

260. (Amended) The composition of claim 245, wherein said binding matrix comprises a member selected from the group consisting of a polypeptide, a polynucleotide, [and a polysaccharide, or a combinantion thereof.

261. (Amended) The composition of claim 245, wherein said polymeric interactions are selected from the group consisting of ionic interactions, hydrogen bonding, dipole-dipole interactions, [or] and a combination of the foregoing.

262. (Amended) The composition of claim 261, wherein said ionic interactions comprise polycationic interactions or [polycationic] polyanionic interactions.

BEST AVAILABLE COPY

Enz-53(D2)

Elazar Rabbani et al. Serial No.: 08/978,634 Filed: November 25, 1997

Page 5 [Amendment Under 37 C.F.R. §1.115 (In Response

to the February 16, 1999 Office Action - August 17, 1999]

2

275. (Amended) A multimeric composition comprising more than one component attached to a charged polymer, wherein said charged polymer is selected from the group consisting of a polycationic polymer, a [polyionic] anionic polymer, a polynucleotide, a modified polynucleotide, [and] a polynucleotide analog, [or] and a combination of the foregoing.

D6

277. (Amended) The multimeric composition of claim 276, wherein said protein is selected from the group consisting of an antibody, [and] an F(ab')2 fragment, [or] and both.

Claim 279, second line, after "antibody is further" and before "with a target"

—change "complex" to -- complexed -- .

\* \* \* \* \* \* \*